The effect of sucrose hydrolysis on the stability of protein therapeutics during accelerated formulation studies

Journal of Pharmaceutical Sciences

Volumn 98, Issue 12, 2009, Pages 4501-4510

  Banks, Douglas D ^a   Hambly, David M ^a   Scavezze, Joanna L ^a   Siska, Christine C ^a   Stackhouse, Nicole L ^a   Gadgil, Himanshu S ^a  

^a AMGEN INC   (United States)

Author keywords

Aggregation; Chemical stability; High performance pressure liquid chromatography (HPLC); Kinetics; Mass spectrometry; Physical stability; Protein; Protein formulation

Indexed keywords

GLUCOSE; IMMUNOGLOBULIN G1; SORBITOL; SUCROSE;

ARTICLE; CONTROLLED STUDY; HYDROLYSIS; PH; PROTEIN GLYCOSYLATION; PROTEIN STABILITY; TEMPERATURE;

EID: 71649111437     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21749     Document Type: Article

References (18)

1. Projan SJ, Gill D, Lu Z, Herrmann SH. 2004. Small molecules for small minds? The case for biologic pharmaceuticals. Expert Opin Biol Therapy 4:1345-1350. (Pubitemid 39005739)
2. Maggon K. 2007. Monoclonal antibody "gold rush". Curr Med Chem 14:1978-1987.
3. Ledford H. 2008. Monoclonal antibodies come of age. Nature 455:437.
4. Frokjaer S, Otzen D. 2005. Protein drug stability: A formulation challenge. Nat Rev Drug Discov 4:298-306. (Pubitemid 41130943)
5. Maas C, Hermeling S, Bouma B, Jiskoot W, Gebbink MFBG. 2007. A role for protein misfolding in immunogenicity of biopharmaceuticals. J Biol Chem 282:2229-2236. (Pubitemid 47076754)
6. Chang BS, Hershenson S. 2002. Practical approaches to protein formulation development. In: Carpenter JF, Manning MC, editors. Rational design of stable protein formulations theory and practice. 1st edition. New York: Kluwer Academic/Plenum Publishers. pp. 1-25.
7. Wang W. 1999. Instability, stabilization, and formulation of liquid protein pharmaceuticals. Int J Pharm 185:129-188. (Pubitemid 29392904)
8. Gadgil HS, Bondarenko PV, Pipes G, Rehder D, Mcauley A, Perico N, Dillon T, Ricci M, Treuheit M. 2007. The LC/MS analysis of glycation of IgG molecules in sucrose containing formulations. J Pharm Sci 96:2607-2621. (Pubitemid 47597812)
9. Quan C, Alcala E, Petkovska I, Matthews D, Canova-Davis E, Taticek R, Ma S. 2008. A study in glycation of a therapeutic recombinant humanized monoclonal antibody: Where it is, how it got there, and how it affects charge-based behavior. Anal Biochem 373:179-191.
10. Zhang B, Yang Y, Yuk I, Pai R, McKay P, Eigenbrot C, Dennis M, Katta V, Francissen KC. 2008. Unveiling a glycation hot spot in a recombinant humanized monoclonal antibody. Anal Chem 80:2379-2390.
11. Brady LJ, Martinez T, Balland A. 2007. Characterization of nonenzymatic glycation on a monoclonal antibody. Anal Chem 79:9403-9413. (Pubitemid 350276319)
12. Fischer S, Hoernschemeyer J, Mahler HC. 2008. Glycation during storage and administration of monoclonal antibody formulations. Eur J Pharm Biopharm 70:42-50.
13. Cho SJ, Roman G, Yeboah F, Konishi Y. 2007. The road to advanced glycation end products: A mechanistic perspective. Curr Med Chem 14:1653-1671. (Pubitemid 47010154)
14. Horvat S, Jakas A. 2004. Peptide and amino acid glycation: New insights into the Maillard reaction. J Peptide Sci 10:119-137. (Pubitemid 38477090)
15. Khalifah RG, Baynes JW, Hudson BG. 1999. Amadorins: Novel post-amadori inhibitors of advanced glycation reactions. Biochem Biophys Res Commun 257:251-258.
16. L'homme C, Arbelot M, Puigserver A, Biagini A. 2003. Kinetics of hydrolysis of fructooligosaccharides in mineral-buffered aqueous solutions: Influence of pH and temperature. J Agric Food Chem 51:224-228.
17. Sattarahmady N, Moosavi-Movahedi AA, Ahmad F, Hakimelahi GH, Habibi-Rezaei M, Saboury AA, Sheibani N. 2007. Formation of the molten globule-like state during prolonged glycation of human serum albumin. Biochim Biophys Acta 1770:933-942. (Pubitemid 46628994)
18. Luthra M, Balasubramanian D. 1993. Nonenzymatic glycation alters protein structure and stability. J Biol Chem 268:18119-18127.